Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
3.900
-0.090 (-2.26%)
Oct 11, 2024, 4:00 PM EDT - Market closed

Company Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet’s Disease.

The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19.

The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009.

Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Soligenix, Inc.
Soligenix logo
Country United States
Founded 1987
IPO Date Jun 15, 1987
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Christopher Schaber

Contact Details

Address:
29 Emmons Drive, Suite B-10
Princeton, New Jersey 08540
United States
Phone (609) 538-8200
Website soligenix.com

Stock Details

Ticker Symbol SNGX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000812796
CUSIP Number 834223307
ISIN Number US8342235053
Employer ID 41-1505029
SIC Code 2834

Key Executives

Name Position
Dr. Christopher J. Schaber Ph.D. Chairman of the Board of Directors, Chief Executive Officer and President
Jonathan L. Guarino CPA, CGMA Senior Vice President, Chief Financial Officer and Corporate Secretary
Dr. Oreola Donini Ph.D. Senior Vice President and Chief Scientific Officer
Dr. Richard C. Straube M.D., MSc. Senior Vice President and Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 11, 2024 8-K Current Report
Aug 16, 2024 424B5 Filing
Aug 16, 2024 8-K Current Report
Aug 9, 2024 424B3 Prospectus
Aug 9, 2024 424B3 Prospectus
Aug 9, 2024 10-Q Quarterly Report
Aug 2, 2024 EFFECT Notice of Effectiveness
Jul 29, 2024 UPLOAD Filing
Jul 25, 2024 8-K Current Report
Jul 24, 2024 S-1 General form for registration of securities under the Securities Act of 1933